Nanoparticles Based Nanomedicine and Vaccines Development

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Adjuvants".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 1792

Special Issue Editor

Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA
Interests: immunology; pharmaceutical science; drug delivery; therapy; nanomaterials

Special Issue Information

Dear Colleagues,

In recent years, the scientific and medical communities have reported the use of nanotechnology/biotechnology, nanomedicine, and vaccines on the improved management of various diseases and viruses. The early detection of the diseases and effective treatment with nanomedicine for targeted therapy has led to significant progress in accelerating precision nanomedicine applications. The use of nanobiotechnology for the development of nanomedicine to deliver small molecules, peptides, genes, and other therapeutics offer improved pharmacokinetics, pharmacodynamics, and safety profiles. The nanomedicine can be developed through encapsulation of drug into nanoparticles, conjugation of specific targeting ligand on nanoparticles, and chemical and physical interaction with multifunction properties would allow for effective therapy at early stage of diseases. 

Nanobiotechnology also plays a key role in vaccines development. Especially in the last 3 years since the COVID-19 pandemic began, nanobiotechnology has offered a range of applications to deal with the pandemic world. The vaccines of COVID-19 have been developed based on nanoscaled mRNA. This showed the potential of nanobiotechnology in health care systems. Nanoparticles-based vaccines offer exceptional benefits over other vaccines. Nanoparticles-based vaccines provide safety, controlled delivery, long term stability, more efficacy toward the virus, and development of strong immune systems. 

The scope of this Special Issue is to cover recent progress in nanobiotechnology as it related to nanomedicine and vaccines. A key aim is to bring the latest advances of various nanomedicine approaches for the detection and treatment of various types of diseases. Further vaccine development research is more important for treatment of COVID-19. Additionally, this issue aims to cover the nanoparticles-based drug delivery and pharmaceutical development and impact on disease prevention.

Dr. Raj Kumar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • nanomedicine
  • drug delivery
  • vaccine
  • biomedical

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1976 KiB  
Article
ProLonged Liposomal Delivery of TLR7/8 Agonist for Enhanced Cancer Vaccine
by Sehui Kim, Yeji Park, Jeonghun Kim, Sohyun Kim, Kyungmin Choi, Taegyun Kang, Inho Lee, Yong Taik Lim, Soong Ho Um and Chul Kim
Vaccines 2023, 11(9), 1503; https://doi.org/10.3390/vaccines11091503 - 19 Sep 2023
Viewed by 1399
Abstract
Despite numerous studies on cancer treatment, cancer remains a challenging disease to cure, even after decades of research. In recent years, the cancer vaccine has emerged as a promising approach for cancer treatment, offering few unexpected side effects compared to existing therapies. However, [...] Read more.
Despite numerous studies on cancer treatment, cancer remains a challenging disease to cure, even after decades of research. In recent years, the cancer vaccine has emerged as a promising approach for cancer treatment, offering few unexpected side effects compared to existing therapies. However, the cancer vaccine faces obstacles to commercialization due to its low efficacy. Particularly, the Toll-like receptor (TLR) adjuvant system, specifically the TLR 7/8 agonist, has shown potential for activating Th1 immunity, which stimulates both innate and adaptive immune responses through T cells. In this study, we developed ProLNG-S, a cholesterol-conjugated form of resiquimod (R848), to enhance immune efficacy by stimulating the immune system and reducing toxicity. ProLNG-S was formulated as ProLNG-001, a positively charged liposome, and co-administered with ovalbumin (OVA) protein in the B16-OVA model. ProLNG-001 effectively targeted secondary lymphoid organs, resulting in a robust systemic anti-tumor immune response and tumor-specific T cell activation. Consequently, ProLNG-001 demonstrated potential for preventing tumor progression and improving survival compared to AS01 by enhancing anti-tumor immunity. Full article
(This article belongs to the Special Issue Nanoparticles Based Nanomedicine and Vaccines Development)
Show Figures

Figure 1

Back to TopTop